Hemoadsorption therapy with a clinically approved device (CytoSorbTM) removes cytokines (interleukin-6, interleukin-10, and tumor necrosis factor, amongst others) and improves short-term survival in a rat model of endotoxemia [47, 48] [1, 3, 4]. The gene discussed is TNF; the disease is serum lipopolysaccharide activity.